Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Cardiovasc. Med., 27 June 2025

Sec. Cardiovascular Pharmacology and Drug Discovery

Volume 12 - 2025 | https://doi.org/10.3389/fcvm.2025.1636315

Correction: Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system

This article is a correction to:

  1. Adverse Events Associated with Amlodipine: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System

    1. Read original article
Jiazhen JiangJiazhen Jiang1Qian ZhongQian Zhong2Xinyu ZhouXinyu Zhou1Lisi ZhouLisi Zhou3Jiyuan ZhengJiyuan Zheng1Bingshuo LiuBingshuo Liu4Xingwei Di Xingwei Di5*
  • 1The First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
  • 2Department of Cardiovascular Medicine, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
  • 3Clinical Medical College of Acupuncture, Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
  • 4The Fifth Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
  • 5Department of Cardiovascular Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

A Correction on

Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system

By Jiang J, Zhong Q, Zhou X, Zhou L, Zheng J, Liu B and Di X (2025). Front. Cardiovasc. Med. 12:1504671. doi: 10.3389/fcvm.2025.1504671

The order of authors in the author list of the published paper was erroneously given as: Xingwei Di, Jiazhen Jiang, Qian Zhong, Xinyu Zhou, Lisi Zhou, Jiyuan Zheng, and Bingshuo Liu. The correct author list reads: Jiazhen Jiang, Qian Zhong, Xinyu Zhou, Lisi Zhou, Jiyuan Zheng, Bingshuo Liu and Xingwei Di. The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: amlodipine, adverse drug reactions, FDA adverse event reporting system, risk signal detection, logistic regression

Citation: Jiang J, Zhong Q, Zhou X, Zhou L, Zheng J, Liu B and Di X (2025) Correction: Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system. Front. Cardiovasc. Med. 12:1636315. doi: 10.3389/fcvm.2025.1636315

Received: 27 May 2025; Accepted: 11 June 2025;
Published: 27 June 2025.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright: © 2025 Jiang, Zhong, Zhou, Zhou, Zheng, Liu and Di. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xingwei Di, ZHh3d3d3MDkyOUAxNjMuY29t

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.